

INFORMATION

Quality / Regulatory Affairs



EIP-0067

Revision 8

Date of issue: 17.01.2024

1/1

Californian Proposition 65

MEGGLE Products:

- Lactose Monohydrate: CapsuLac[®] 60, FlowLac[®] 90, FlowLac[®] 90 MS, FlowLac[®] 100, FlowLac[®] 90 MS, FlowLac[®] 100 SD, GranuLac[®] 70, GranuLac[®] 70 MS, GranuLac[®] 80, GranuLac[®] 140, GranuLac[®] 140 S, GranuLac[®] 200, GranuLac[®] 200 MS, GranuLac[®] 200 S, GranuLac[®] 230, InhaLac[®] 70, InhaLac[®] 120, InhaLac[®] 140, InhaLac[®] 145, InhaLac[®] 150, InhaLac[®] 160, InhaLac[®] 180, InhaLac[®] 230, InhaLac[®] 251, InhaLac[®] 300, InhaLac[®] 400, InhaLac[®] 500, Lactose Monohydrate 200 Mesh IP, Lactose Monohydrate Impalpable, Lactose Monohydrate Low Endotoxin, PrismaLac[®] 40, SacheLac[®] 80, SorboLac[®] 400, SpheroLac[®] 100, Tablettose[®] 70, Tablettose[®] 80, Tablettose[®] 100, Tablettose[®] 100 MS

- Co-processed Excipients: Cellactose[®] 80, CombiLac[®], MicroceLac[®] 100, RetaLac[®], StarLac[®]

The above mentioned MEGGLE Products are safe as pharmaceutical excipient and as food e.g. in food supplements.

Residues and contaminants in above mentioned products are monitored. The products or the used compounds in co-processed excipients comply with the relevant pharmaceutical monograph and relevant food laws and cause no significant risk of harm when they are used.

Substances known to the State of California to cause cancer or birth defects or other reproductive harm are not used for the production of above mentioned products. To the best of our knowledge, due to the highly refined and purified nature of the products no Proposition 65 chemicals are expected in the product.

This MEGGLE Information was electronically released and is valid without signature.